Dual Agonist (GLP-1 / GIP) – COMPREHENSIVE RESEARCH PEPTIDE FOR INCRETIN AND DUAL RECEPTOR SIGNALING STUDIES

Scientific Overview of Dual Agonist (GLP-1 / GIP)

Dual Agonist (GLP-1 / GIP) is a synthetic dual receptor agonist peptide that acts on both the Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors. It is structurally based on the native GIP sequence, modified to include fatty acid side-chain conjugation for increased plasma stability and receptor binding persistence.

In preclinical and mechanistic studies, Dual Agonist (GLP-1 / GIP) has been investigated for its role in metabolic and endocrine research models, focusing on:

• Dual Receptor Activation – exploration of concurrent GLP-1R and GIPR binding and downstream cAMP pathway signaling (Frias et al., 2018)
• Metabolic Pathway Integration – study of peptide-mediated modulation of glucose metabolism and lipid utilization (Coskun et al., 2018)
• Structural Optimization and Acylation Modifications – evaluation of long-chain fatty acid conjugation and receptor selectivity enhancements (Willard et al., 2020)

This peptide serves as a key research tool for examining incretin biology, dual receptor dynamics, and peptide engineering aimed at understanding complex metabolic signaling processes.